Clarus Therapeutics Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Clarus Therapeutics Holdings Inc (CRXT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Clarus Therapeutics Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 17M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-4.2% annualized vs trailing 12 months).
- Peer revenue share: Clarus Therapeutics Holdings Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CRXT Sales vs. its Competitors, Q2 2022
Clarus Therapeutics Holdings Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs 45.7% for Clarus Therapeutics Holdings Inc. Clarus Therapeutics Holdings Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.